Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

93 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Unveiling the Clinical and Imaging Signatures of Intravascular Lymphoma of the Central Nervous System: A Multicentric Cohort Study.
Berthet E, Guillonnet A, Houillier C, Ursu R, Soussain C, Touat M, Gueguen A, de Renzis B, Bigaut K, Ahle G, Durozard P, Grosset-Janin D, Oberic L, Bonnet A, Grandjean AP, Moluçon-Chabrot C, Hoang-Xuan K, Chabriat H, Guey S. Berthet E, et al. Among authors: oberic l. Ann Neurol. 2024 Nov 28. doi: 10.1002/ana.27132. Online ahead of print. Ann Neurol. 2024. PMID: 39605186
Correction: Phase IB part of LOC-R01, a LOC network non-comparative randomized phase IB/II study testing R-MPV in combination with escalating doses of lenalidomide or ibrutinib for newly diagnosed primary central nervous system lymphoma (PCNSL) patients.
Alcantara M, Chevrier M, Jardin F, Schmitt A, Houillier C, Oberic L, Chinot O, Morschhauser F, Peyrade F, Houot R, Hoang-Xuan K, Ghesquieres H, Soussain C. Alcantara M, et al. Among authors: oberic l. J Hematol Oncol. 2024 Oct 19;17(1):98. doi: 10.1186/s13045-024-01620-y. J Hematol Oncol. 2024. PMID: 39427203 Free PMC article. No abstract available.
Phase IB part of LOC-R01, a LOC network non-comparative randomized phase IB/II study testing R-MPV in combination with escalating doses of lenalidomide or ibrutinib for newly diagnosed primary central nervous system lymphoma (PCNSL) patients.
Alcantara M, Chevrier M, Jardin F, Schmitt A, Houillier C, Oberic L, Chinot O, Morschhauser F, Peyrade F, Houot R, Hoang-Xuan K, Ghesquieres H, Soussain C. Alcantara M, et al. Among authors: oberic l. J Hematol Oncol. 2024 Sep 19;17(1):86. doi: 10.1186/s13045-024-01606-w. J Hematol Oncol. 2024. PMID: 39300447 Free PMC article. Clinical Trial.
MYC Rearrangement Prediction From LYSA Whole Slide Images in Large B-Cell Lymphoma: A Multicentric Validation of Self-supervised Deep Learning Models.
Syrykh C, Di Proietto V, Brion E, Copie-Bergman C, Jardin F, Dartigues P, Gaulard P, Molina TJ, Briere J, Oberic L, Haioun C, Tilly H, Maussion C, Morel M, Schiratti JB, Laurent C. Syrykh C, et al. Among authors: oberic l. Mod Pathol. 2024 Dec;37(12):100610. doi: 10.1016/j.modpat.2024.100610. Epub 2024 Sep 10. Mod Pathol. 2024. PMID: 39265953
Outcome of patients with large B-cell lymphoma treated with tafasitamab plus lenalidomide either before or after CAR T-cell therapy.
Camus V, Houot R, Brisou G, Tessoulin B, Bailly S, Sesques P, Decroocq J, Krzisch D, Oberic L, Lemonnier F, Bouabdallah K, Campidelli A, Tounes L, Abraham J, Herbaux C, Morschhauser F, Damaj GL, Guidez S, Carras S, Fornecker LM, Choquet S, Hermine O, Paillassa J, Chauchet A, Casasnovas O, Drieu La Rochelle L, Castilla-Llorente C, Joris M, Dupont V, Marquet A, Le Gouill S, Jardin F. Camus V, et al. Among authors: oberic l. Blood Adv. 2024 Oct 22;8(20):5371-5381. doi: 10.1182/bloodadvances.2024013726. Blood Adv. 2024. PMID: 39163620 Free PMC article.
Author Correction: Axicabtagene ciloleucel as second-line therapy in large B cell lymphoma ineligible for autologous stem cell transplantation: a phase 2 trial.
Houot R, Bachy E, Cartron G, Gros FX, Morschhauser F, Oberic L, Gastinne T, Feugier P, Duléry R, Thieblemont C, Joris M, Jardin F, Choquet S, Casasnovas O, Brisou G, Cheminant M, Bay JO, Gutierrez FL, Menard C, Tarte K, Delfau MH, Portugues C, Itti E, Palard-Novello X, Blanc-Durand P, Al Tabaa Y, Bailly C, Laurent C, Lemonnier F. Houot R, et al. Among authors: oberic l. Nat Med. 2024 Jul;30(7):2089. doi: 10.1038/s41591-024-03053-z. Nat Med. 2024. PMID: 38745012 Free PMC article. No abstract available.
Obinutuzumab vs rituximab for transplant-eligible patients with mantle cell lymphoma.
Sarkozy C, Callanan M, Thieblemont C, Obéric L, Burroni B, Bouabdallah K, Damaj G, Tessoulin B, Ribrag V, Houot R, Morschhauser F, Griolet S, Joubert C, Cacheux V, Delwail V, Safar V, Gressin R, Cheminant M, Delfau-Larue MH, Hermine O, Macintyre E, Le Gouill S. Sarkozy C, et al. Among authors: oberic l. Blood. 2024 Jul 18;144(3):262-271. doi: 10.1182/blood.2024023944. Blood. 2024. PMID: 38669626 Free article. Clinical Trial.
93 results